Acumen Pharmaceuticals(ABOS) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ABOS Acumen Pharmaceuticals

Watchlist

1.270
+0.010+0.79%

Close Mar 19 16:00 ET

1.270
0.0000.00%

Post 20:01 ET

76.30MMarket Cap-0.92P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Acumen Meets Safety Goals in Early Stage Trial of Its Alzheimer's Treatment
Seeking AlphaMar 19 09:01 ET
Express News | Acumen Pharmaceuticals Inc - Phase 2 Altitude-Ad Study of IV Sabirnetug Ongoing
ReutersMar 19 08:00 ET
Acumen Pharmaceuticals Announces Topline Results From Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
GlobeNewswireMar 19 08:00 ET
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
GlobeNewswireMar 18 08:48 ET
Acumen Pharmaceuticals Announces Upcoming Scientific Presentations On Alzheimer's Therapeutics At AD/PD In Vienna And AAN Annual Meeting In San Diego April 2025
BenzingaMar 12 08:02 ET
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
GlobeNewswireJan 9 08:00 ET

Comments

Teddy123

14 hours ago

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

$Acumen Pharmaceuticals (ABOS.US)$
Breakthrough in Alzheimer's Treatment: Acumen's New Injectable Drug Shows Promise in Phase 1

Trytosaveabit

Jan 10 03:32

Update Thursday 1/9/25

$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
GlobeNewswire· 08:0011mins
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated selectiv...

Jaguar8

Jan 9 22:04

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
1 hour ago, 5:00 AM PST
Via GlobeNewswire
ABOS
Share
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated ...

Jaguar8

Oct 31, 2024 20:20

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease
Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifie...